Creo Medical Group PLC’s (LON:CREO) CEO, Craig Gulliford said that the company’s core products are driving growth and improving results.
There is a clear line to profitability now, he says, highlighting a doubling of patients treated using its endoscopy technology.
A recent acquisition in Europe lays the base for growth here, he adds, while customer demand generally is pulling it increasingly towards the robotic space.
#Creo Medical #AIM #Med-tech
